Fox CP, Ahearne MJ, Ruth P, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196(3):507–22.

Article  PubMed  Google Scholar 

Lansigan F, Horwitz SM, Pinter-Brown LC, et al. Outcomes for relapsed and refractory peripheral T-Cell lymphoma patients after front-line therapy from the COMPLETE registry. Acta Haematol. 2020;143(1):40–50.

Article  PubMed  Google Scholar 

Quintás-Cardama A, Verstovsek S, Freireich E, et al. Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. Anticancer Agents Med Chem. 2008;8(8):904–9.

Article  PubMed  Google Scholar 

Mann KK, Wallner B, Lossos IS, et al. Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs. 2009;18(11):1727–34.

Article  CAS  PubMed  Google Scholar 

Fukuhara N, Kim WS, Yoon DH, et al. Asian multinational phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma [abstract no. 1376]. Blood. 2021;138(Suppl 1):1376.

Article  Google Scholar 

Solasia Pharma K.K. DARVIAS® Injection 135mg: Japanese prescribing information. 2022

Solasia Pharma K.K. DARVIAS® Injection 135mg (generic name: DARINAPARSIN/development code: SP-02) approved in Japan [media release]. 2022. https://ssl4.eir-parts.net/doc/4597/tdnet/2144731/00.pdf. Accessed 20 Jun 2022

Solasia Pharma K.K. SP-02 overview—pipeline information. https://solasia.co.jp/en/pipeline/sp02.html. Accessed 27 Sep 2022.

Hosein PJ, Craig MD, Tallman MS, et al. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma. Am J Hematol. 2012;87(1):111–4.

Article  CAS  PubMed  Google Scholar 

Berenson JR, Jaganath S, Reece D, et al. ZIO-101 (S-dimethylarsino-glutathione): phase I/II trials in advanced/ progressive multiple myeloma. J Clin Oncol. 2007;25(Suppl. 18):468.

Google Scholar 

Tsimberidou AM, Camacho LH, Verstovsek S, et al. A phase I clinical trial of darinapars in in patients with refractory solid tumors. Clin Cancer Res. 2009;15(14):4769–76.

Article  CAS  PubMed  Google Scholar 

Wu J, Henderson C, Feun L, et al. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2010;28(5):670–6.

Article  CAS  PubMed  Google Scholar 

Ziopharm Inc. ZIOPHARM starts phase I study of ZIO-101 [media release]. 2005. http://www.ziopharm.com. Accessed 19 May 2005.

Ziopharm Oncology Inc. ZIOPHARM and Solasia Pharma announce license and collaboration agreement for darinaparsin in Asia [media release]. 2011. http://www.ziopharm.com. Accessed 8 Mar 2011.

Ziopharm Oncology Inc. ZIOPHARM Oncology and Solasia Pharma announce global license and collaboration agreement for darinaparsin [media release]. 2014. http://www.ziopharm.com. Accessed 31 Jul 2014.

Solasia Pharma K.K. Announcement concerning signing of license and distribution agreement for SP-02 (darinaparsin injection) in Latin America [media release]. 2018. http://www.solasia.co.jp. Accessed 17 Aug 2018.

Solasia Pharma K.K. Solasia and Nippon Kayaku announce license agreement in Japan for new drug candidate DARINAPARSIN (SP-02) [media release]. 2021. http://solasia.co.jp. Accessed 26 Oct 2021.

Ziopharm Oncology Inc. Ziopharm Oncology highlights operational progress rebrands to Alaunos Therapeutics [media release]. 2022. http://www.alaunos.com. Accessed 26 Jan 2022.

Diaz Z, Mann KK, Marcoux S, et al. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia. 2008;22(10):1853–63.

Article  CAS  PubMed  Google Scholar 

Ravi D, Bhalla S, Gartenhaus RB, et al. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models. Clin Cancer Res. 2014;20(23):6023–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matulis SM, Morales AA, Yehiayan L, et al. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther. 2009;8(5):1197–206.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khairul I, Wang QQ, Jiang YH, et al. Metabolism, toxicity and anticancer activities of arsenic compounds. Oncotarget. 2017;8:23905–26.

Article  PubMed  PubMed Central  Google Scholar 

Mason TA, Kolobova E, Liu J, et al. Darinaparsin is a multivalent chemotherapeutic which induces incomplete stress response with disruption of microtubules and Shh signaling. PLoS ONE. 2011;6(11): e27699.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Camacho LH, Hong DS, Verstovek S, et al. Phase-1 trial of ZIO-101, a novel organic arsenic in advanced cancer [abstract no. 413P]. Ann Oncol. 2006;17(Suppl. 9):ix138.

Google Scholar 

Garnier N, Redstone GG, Dahabieh MS, et al. The novel arsenical darinaparsin is transported by cystine importing systems. Mol Pharmacol. 2014;85(4):576–85.

Article  PubMed  Google Scholar 

Ohno N, Tani A, Chen ZS, et al. Prognostic significance of multidrug resistance protein in adult T-cell leukemia. Clin Cancer Res. 2001;7:3120–6.

CAS  PubMed  Google Scholar 

Ogura M, Kim WS, Uchida T, et al. Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea. Jpn J Clin Oncol. 2021;51(2):218–27.

Article  PubMed  Google Scholar